Omada Health (NASDAQ:OMDA) Issues Quarterly Earnings Results

Omada Health (NASDAQ:OMDA) posted its quarterly earnings data on Thursday. The company reported $0.10 earnings per share for the quarter, topping the consensus estimate of $0.02 by $0.08, FiscalAI reports. Omada Health had a net margin of 1.39% and a return on equity of 2.60%. The firm had revenue of $91.31 million for the quarter.

Here are the key takeaways from Omada Health’s conference call:

• Positive Sentiment: Omada reported record Q3 revenue of $91 million, up 34% year over year, and adjusted EBITDA of $12 million. It raised 2026 guidance to $344–$346 million in revenue and $32–$34 million in adjusted EBITDA.
• Positive Sentiment: Total members reached 1.134 million, up 36% year over year, while average program tenure rose to about two years and four months. Management said the stronger mix of diabetes and hypertension programs and lower cost to serve helped drive gross margin expansion and profitability.
• Positive Sentiment: Omada cited broader distribution through its PBM relationships and an HCSC agreement that could add an estimated 1.5 million covered lives across three states in 2027. The company said the fully insured benefit arrangement enables eligible members to enroll directly when it launches.
• Negative Sentiment: Management expects Q4 revenue below Q3 levels and a slight sequential decline in total members, reflecting typical seasonality and fewer new enrollments. The selling season has also extended into Q4 as employers take longer to weigh GLP-1 coverage and rising healthcare costs, leaving 2027 enrollment visibility unsettled.

Omada Health Trading Down 18.2%

OMDA stock traded down $3.45 during midday trading on Friday, reaching $15.50. The company had a trading volume of 2,494,542 shares, compared to its average volume of 1,258,707. The company has a 50 day moving average of $20.33 and a two-hundred day moving average of $17.74. The company has a market capitalization of $948.91 million, a P/E ratio of 310.00 and a beta of 2.13. Omada Health has a 1 year low of $10.28 and a 1 year high of $25.45.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the company. JPMorgan Chase & Co. raised their target price on Omada Health from $26.00 to $30.00 and gave the stock an “overweight” rating in a research report on Friday, August 14th. Citigroup reiterated an “outperform” rating on shares of Omada Health in a report on Friday, August 14th. Wall Street Zen raised Omada Health from a “hold” rating to a “buy” rating in a research report on Sunday, October 11th. Robert W. Baird increased their price objective on Omada Health from $15.00 to $25.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 12th. Finally, BMO Capital Markets restated an “outperform” rating and set a $24.00 price objective on shares of Omada Health in a research report on Friday, August 7th. Eleven equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Omada Health presently has a consensus rating of “Moderate Buy” and an average price target of $26.33.

Key Headlines Impacting Omada Health

Here are the key news stories impacting Omada Health this week:

• Positive Sentiment: Q3 revenue rose 34% year over year to $91 million, beating estimates, while total members grew 36% to a record 1.1 million. Omada also swung to $7 million in net income from a $3 million loss a year earlier, and adjusted EBITDA increased to $12 million from $2 million. Gross margin improved, and the company raised its full-year 2026 financial outlook. Omada Health Reports Third Quarter 2026 Results
• Neutral Sentiment: OMDA was among stocks with unusual options volume after earnings. The activity signals heightened trading interest but does not indicate a clear direction for the shares. Unusual Options Volume Report
• Negative Sentiment: Several analysts took a more cautious stance. Barclays lowered its price target from $24 to $22 but maintained an Overweight rating; Wells Fargo cut its target from $22 to $19 and kept an Equal Weight rating. Zacks Research downgraded OMDA from Strong Buy to Hold. These revisions may temper enthusiasm following the earnings beat. Barclays rating information Wells Fargo rating information Zacks Research rating information

Insider Activity

In other news, President Wei-Li Shao sold 8,866 shares of the company’s stock in a transaction on Wednesday, August 12th. The shares were sold at an average price of $25.02, for a total value of $221,827.32. Following the transaction, the president directly owned 307,372 shares of the company’s stock, valued at approximately $7,690,447.44. This represents a 2.80% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Steven Cook sold 15,235 shares of the stock in a transaction on Monday, August 10th. The stock was sold at an average price of $25.03, for a total value of $381,332.05. Following the sale, the chief financial officer owned 187,209 shares of the company’s stock, valued at approximately $4,685,841.27. This represents a 7.53% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 106,070 shares of company stock worth $2,462,621 in the last ninety days. Corporate insiders own 6.38% of the company’s stock.

Institutional Investors Weigh In On Omada Health

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Sterling Capital Management LLC boosted its stake in shares of Omada Health by 1,161.6% during the 3rd quarter. Sterling Capital Management LLC now owns 1,577 shares of the company’s stock worth $33,000 after acquiring an additional 1,452 shares in the last quarter. Integrated Wealth Concepts LLC acquired a new position in Omada Health during the 2nd quarter worth $53,000. State of Alaska Department of Revenue acquired a new stake in shares of Omada Health in the third quarter valued at about $59,000. Versant Capital Management Inc grew its holdings in Omada Health by 319.3% in the 2nd quarter. Versant Capital Management Inc now owns 2,998 shares of the company’s stock valued at $66,000 after buying an additional 2,283 shares during the last quarter. Finally, Legal & General Group Plc bought a new stake in shares of Omada Health in the second quarter valued at approximately $76,000.

Omada Health Company Profile

Omada Health, Inc (NASDAQ: OMDA) is a digital health company that provides virtual care programs for people managing chronic conditions. Its platform combines personalized health coaching, clinical support, behavioral-change tools and connected devices to help members monitor and improve their health.

The company’s offerings focus primarily on cardiometabolic conditions, including diabetes, prediabetes, hypertension and obesity, as well as musculoskeletal conditions. Depending on the program, members may receive access to digital lessons, health tracking, remote monitoring, care teams and clinical guidance through Omada’s technology platform.

Omada Health was founded in 2011 and serves employers, health plans and other healthcare organizations in the United States.